Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Mirum Pharmaceuticals, Inc.

NASDAQ: MIRM · Life Sciences · 9 alerts · CIK 1759425

Mirum Pharmaceuticals, Inc. stories on ALFA USA NewsRead the news →
Share price
$91.58Close, Nov 16
Market cap
$5.98B
Shares outstanding
65.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mirum Pharmaceuticals, Inc. filings on SEC EDGAR ↗

8:04 AM ET 8-K
Regulatory Approval

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.